Previous Article | Next Article ![]()
Journal of Clinical Microbiology, January 1998, p. 219-222, Vol. 36, No. 1
Division of Infectious Diseases,
Received 27 June 1997/Accepted 8 October 1997
Staphylococcus aureus isolates which produce type A
staphylococcal Despite the almost universal
administration of antimicrobial agents with good antistaphylococcal
activity for perioperative prophylaxis in patients undergoing clean
surgery, Staphylococcus aureus remains the most common cause
of surgical wound infection (22). While
methicillin-resistant S. aureus (MRSA) accounts for some
wound infections, the majority are caused by methicillin-susceptible strains. Although the reasons for breakthrough infections due to
apparently susceptible strains are not fully understood, isolates which
produce type A staphylococcal In an effort to correlate patterns of S. aureus resistance
with different regimens of perioperative prophylaxis, wound isolates were obtained from 15 hospitals in 14 cities across the United States.
These isolates were evaluated by phage typing, MIC determinations, and
Bacterial isolates.
Between late 1985 and early 1991, a
total of 273 isolates of S. aureus associated with deep
surgical wound infections that developed after clean surgical
procedures were collected by, referred to, or solicited by the authors.
A deep wound infection was defined as a postoperative infection
requiring surgical incision and drainage for treatment. Of the
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Association of Borderline Oxacillin-Susceptible
Strains of Staphylococcus aureus with Surgical Wound
Infections
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
-lactamase have been associated with wound infections complicating the use of cefazolin prophylaxis in surgery. To further evaluate this finding, 215 wound isolates from 14 cities in the United
States were characterized by antimicrobial susceptibility and
-lactamase type and correlated with the preoperative prophylactic regimen. Borderline-susceptible S. aureus isolates of phage
group 5 (BSSA-5), which produce large amounts of type A
-lactamase and exhibit borderline susceptibility to oxacillin, comprised a greater
percentage of the 120 wound isolates associated with cefazolin
prophylaxis than they did of the 95 isolates associated with other
prophylactic regimens (25% versus 12.6%, respectively; P < 0.05). In contrast, methicillin-resistant
S. aureus isolates were distributed evenly between the two
groups (8.3% versus 11.6%, respectively). In vitro assays
demonstrated that cefazolin was hydrolyzed faster by BSSA-5 strains
than by other
-lactamase-producing, methicillin-susceptible strains
(1.54 versus 0.50 µg/min/108 CFU, respectively;
P < 0.0001). These data demonstrate that BSSA-5 strains are a distinct subpopulation of methicillin-susceptible S. aureus which frequently cause deep surgical wound
infections. Cefazolin use in prophylaxis is a risk factor for BSSA-5
infection.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
-lactamase have been associated with
wound infections complicating the use of cefazolin prophylaxis in
surgical patients (9). Type A S. aureus
-lactamase inactivates cefazolin relatively efficiently, conferring
a partial resistance to cefazolin that is not easily identified by
standard tests for determining antibiotic susceptibility (8-10,
29).
-lactamase typing and quantification assays. A subpopulation of
methicillin-susceptible staphylococci identified as
borderline-susceptible S. aureus typeable with group 5 staphylococcal phages (BSSA-5) and characterized by the production of
large amounts of type A staphylococcal
-lactamase and borderline
susceptibility to oxacillin were found to be widely disseminated among
U.S. hospitals and disproportionately isolated from wound infections of
patients who had been given cefazolin prophylaxis. These data suggest
that in the perioperative setting, in vivo degradation of cefazolin may
enable BSSA-5 strains to survive beyond the time of initial lodgement
in wound tissues and, ultimately, to cause infection.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
-lactamase-producing strains, specific information on the patient's
perioperative antibiotic regimen was available for isolates recovered
from 215 deep wound infections. The sources and corresponding numbers
of these isolates are shown in Table 1.
All isolates were confirmed to be S. aureus by established methods, including colony morphology, Gram stain characteristics, the
presence of catalase activity, and the ability to coagulate rabbit
serum (11).
TABLE 1.
Sources of S. aureus wound isolates
-lactamase were used as controls for
-lactamase typing, as well
as in cefazolin degradation assays and time-kill survival studies.
These included PC1(pI524) and NCTC 9789, which produce type A
-lactamase; 22260 and ST79/741, which produce type B
-lactamase; 3804 and RN9(pII147), which produce type C
-lactamase; and FAR10 and
NCTC 9754, which produce type D
-lactamase (8-10, 12, 17, 19,
20, 29). NCTC 10972, the propagating strain for phage 96, was
used as a representative BSSA-5 strain (1, 15), and ATCC
6538P was employed as a non-
-lactamase-producing control.
Antibiotic preparations and media.
Standard powders of
nitrocefin (BBL Microbiology Systems, Cockeysville, Md.), cephaloridine
(Sigma Chemicals, St. Louis, Mo.), methicillin, oxacillin (both from
Bristol Laboratories, Syracuse, N.Y.), penicillin G, cefazolin (both
from Eli Lilly and Company, Indianapolis, Ind.), and clavulanic acid
(SmithKline Beecham Pharmaceuticals, Philadelphia, Pa.) were used to
prepare antimicrobial solutions for susceptibility testing,
-lactamase typing, and antibiotic degradation assays. Tryptic soy
agar and broth and Mueller-Hinton agar and broth were purchased from
Difco Laboratories (Detroit, Mich.). Modified 1% CY-Tris agar with and
without 0.5 µg of methicillin per ml was prepared as previously
described (10, 17).
Susceptibility determinations. Microdilution MICs were determined in accordance with methods described by the National Committee for Clinical Laboratory Standards (16). Cation-supplemented Mueller-Hinton broth with and without 2% sodium chloride was used for determinations with standard (5 × 105 CFU/ml) and large (5 × 107 CFU/ml) inocula, respectively. Trays were incubated at 35°C, and the results were recorded at 24 h.
-Lactamase typing and quantitation.
The type and amount
of
-lactamase produced by each strain following
-lactamase
induction by growth on agar containing 0.5 µg of methicillin per ml
were determined using whole-cell suspensions of bacteria, as previously
described (10). Hydrolysis assays were performed with 100 µM solutions of nitrocefin, cefazolin, and cephaloridine and a 500 µM solution of penicillin G at 37°C in 1-cm-light path cuvettes in
a DU-70 recording spectrophotometer (Beckman Instruments, Fullerton,
Calif.). Quantitative rates were corrected for small variations in the
absorbance at 272 nm (A272) of different
whole-cell preparations and reported as micromoles (or micrograms) of
substrate degraded per minute per standard cell mass
(A272 = 1.0, or approximately 108
CFU).
Phage typing. Bacteriophage typing was performed with the international set of phages at the standard test dilution and 100-fold routine test dilution concentrations (25). The following phages were used: lytic group 1 phages 29, 52, 52A, 79, and 80; lytic group 2 phages 3A, 3C, 55, and 71; lytic group 3 phages 6, 42E, 47, 53, 54, 75, 77, 83A, 84, and 85; lytic group 5 phages 94 and 96; and nonallocated phages 81 and 95.
Antibiotic degradation assays.
After growth on tryptic soy
agar for 18 h at 37°C, colonies of S. aureus were
suspended in 15 ml of 2% salt-supplemented, cation-supplemented
Mueller-Hinton broth and adjusted spectrophotometrically to a density
of 1.5 × 108 CFU/ml. Cefazolin was added immediately
to a final concentration of 50 µg/ml. Mixtures were incubated at
37°C, and 2-ml aliquots were withdrawn at 6, 12, and 24 h for
determination of residual cefazolin levels. Each sample was immediately
filter sterilized (0.2-µm-pore-size filter), and 20-µl portions
were added to 6-mm-diameter paper discs (BBL) previously impregnated
with 0.08 µg of clavulanic acid, a manipulation which was shown to be
necessary and adequate to prevent further
-lactamase-mediated
degradation of cefazolin. Cefazolin levels were determined by bioassay
methods using antibiotic medium 1 (Difco) and S. aureus ATCC
6538P as the indicator organism (3).
Definitions.
S. aureus isolates were classified as
either susceptible to penicillin G (MIC,
0.12 µg/ml), penicillin
resistant and methicillin susceptible (penicillin G MIC,
0.25
µg/ml; methicillin MIC,
8 µg/ml), or methicillin resistant (MIC,
16 µg/ml) by using recommended criteria (16). Strains
susceptible to penicillin G were not evaluated further. The
penicillin-resistant, methicillin-susceptible isolates were grouped on
the basis of whether they exhibited the borderline-susceptible
phenotype. Isolates were designated BSSA if they exhibited penicillin G
MICs of
64 µg/ml, oxacillin MICs of 0.5 to 4.0 µg/ml, and
methicillin MICs of 2 to 4 µg/ml and had nitrocefin degradation rates
of >0.060 µmol per min per standard cell mass (with
A272 = 1.0) (1, 14, 15). BSSA
isolates typeable with phage 94 and/or phage 96 were designated BSSA-5.
Statistical analysis.
Comparisons of the rates of
cephalosporin hydrolysis and MICs were performed with the two-sample
t test and the Wilcoxon rank sum test, respectively.
Comparisons of differences in the proportions of BSSA-5 strains from
various sources were determined by performing chi-square analyses with
Yate's correction. A P value of
0.05 was considered to be
statistically significant.
| |
RESULTS |
|---|
|
|
|---|
Distribution of MRSA and BSSA-5 isolates among wound infections. Of the 215 S. aureus wound isolates from 15 hospitals in 14 cities, 21 (9.8%) were identified as MRSA (Table 1). Fifty-one of the isolates were typeable with phage 94 and/or phage 96 at either the routine dilution (45 isolates) or a 100-fold phage concentration (6 isolates). Strains typeable at the routine dilution were more likely than strains typeable only at a 100-fold phage concentration to exhibit the borderline-susceptible phenotype (41 of 45 versus 1 of 6, respectively; P < 0.0005, two-tailed Fisher's test). Compared to phage group 5 strains, the borderline-susceptible phenotype was observed infrequently among other S. aureus strains; only 4 (2.6%) of the 152 penicillin-resistant, methicillin-susceptible non-phage group 5 isolates met the criteria for borderline susceptibility to the antistaphylococcal penicillins. Overall, 42 (19.5%) of the 215 isolates were typeable with group 5 phages and exhibited borderline susceptibility (i.e., were BSSA-5). At least one MRSA strain was identified among isolates from 10 of the 15 hospitals. Isolates from 10 hospitals, including all 8 of the hospitals from which at least six cefazolin-associated wound isolates were available for evaluation, were identified as being BSSA-5.
Association with prophylactic regimens. One hundred and twenty isolates were recovered from wound infections complicating perioperative prophylaxis with cefazolin (Table 2). Ninety-five wound isolates were recovered from patients on other prophylactic regimens, including cefamandole (53 isolates), cefuroxime (20 isolates), vancomycin (6 isolates), cefoperazone (4 isolates), cefonicid (2 isolates), cefotetan (2 isolates), cefoxitin (1 isolate), ceftizoxime (1 isolate), and no prophylaxis (6 isolates). BSSA-5 isolates were recovered more often from cefazolin-associated wound infections than from infections complicating other prophylactic regimens (25.0% versus 12.6%, respectively; P < 0.05, chi-square with Yate's correction). In contrast, MRSA isolates were distributed evenly between the two groups (8.3% versus 11.6%, respectively). If the MRSA isolates are excluded from this analysis, cefazolin prophylaxis and the isolation of BSSA-5 isolates from the wound infection remain significantly associated (P < 0.05, chi-square with Yate's correction). Because of the large number of isolates from Nashville, the association of BSSA-5 isolates with cefazolin prophylaxis was analyzed for hospitals outside of Nashville. Twenty-four percent of isolates associated with cefazolin prophylaxis were BSSA-5, versus 10.9% of isolates associated with other prophylactic regimens (P = 0.068, chi-square with Yate's correction).
|
Correlation between MICs, rates of cefazolin degradation, and kill-kinetic assays. The MICs and cefazolin hydrolysis rates of the 21 MRSA, 42 BSSA-5, and 152 penicillin-resistant, methicillin-susceptible S. aureus strains were compared (Table 3). BSSA-5 isolates were significantly more resistant to cefazolin than the other methicillin-susceptible strains. The rate of cefazolin hydrolysis was significantly higher for BSSA-5 than for either MRSA or methicillin-susceptible strains.
|
-lactamase-producing strains
recovered from wound infections produced similar results, with mean
residual cefazolin concentrations of 3.7 and 26.9 µg/ml,
respectively, at 6 h (P < 0.005).
|
| |
DISCUSSION |
|---|
|
|
|---|
The term borderline-susceptible (or borderline-resistant) S. aureus became popular after the 1986 report by McDougal and
Thornsberry on S. aureus strains with a distinctive
phenotype which included all of the following properties: (i)
borderline oxacillin MICs, (ii) lowering of oxacillin MICs into the
clearly susceptible range by
-lactamase inhibitors, (iii) rapid
hydrolysis of the chromogenic cephalosporin nitrocefin, and (iv) high
penicillin G MICs (14). These strains produced large amounts
of
-lactamase. Subsequently, we have shown that isolates with all of
these phenotypic characteristics belong almost exclusively to phage
group 5 (i.e., phage 94 and/or phage 96), possess a 17.2-kb plasmid,
and produce large quantities of type A staphylococcal
-lactamase
(1, 7, 15). Portions of this relationship among phage group,
borderline susceptibility, presence of a unique plasmid, and
hyperproduction of
-lactamase have been noted by others (5, 13,
21, 23, 28), and these isolates appear to represent a distinct
subpopulation of S. aureus that is distributed widely among
clinical specimens (4, 28). About 85% of phage group 5 strains are borderline susceptible (15). Genetic analyses,
including determination of SmaI macrorestriction
patterns following pulsed-field gel electrophoresis as well as studies
on the size and restriction polymorphism of the internal spacer between
the 16S and 23S rRNA genes, indicate that there is a high degree of
relatedness among phage group 5 isolates (4).
Terms like borderline resistant, low-level resistant, and borderline
susceptible have also been applied to other isolates of S. aureus that do not exhibit high-level
-lactamase production (24, 27). Most of such strains either have alterations in their normal penicillin-binding proteins, such that they have reduced
binding affinity for
-lactams (26), or contain
mecA, the gene encoding penicillin-binding protein 2a, but
exhibit MICs around the breakpoint between the methicillin-susceptible
and methicillin-resistant designations (2, 6) rather than
the high MICs exhibited by most MRSA strains. Accordingly, to better distinguish isolates with borderline susceptibility due to different mechanisms, in this study we have used the term BSSA-5 to identify S. aureus strains that are typeable with group 5 phages and
exhibit all the phenotypic characteristics identified with the
high-level
-lactamase-producing isolates of S. aureus
described by McDougal and Thornsberry (14).
This study documents the prevalence of MRSA and BSSA-5 in wound infections and compares the prevalence associated with cefazolin prophylaxis to that associated with other prophylactic regimens. MRSA was found to comprise 11.6% of all S. aureaus wound isolates, a value comparable to the 11% prevalence of MRSA among nosocomial S. aureus isolates from U.S. hospitals during this period of time (18). MRSA isolates comprised a similar proportion of the S. aureus wound isolates from patients receiving cefazolin as they did from patients receiving other prophylactic regimens.
BSSA-5 isolates comprised an even larger proportion than MRSA, being
recovered from 19.5% of S. aureus deep wound infections. We
considered several explanations for this finding. BSSA-5 isolates might
possess a special tropism for skin and soft tissues or have some other
virulence attributes enabling them to cause wound infection. We do not
have any evidence to confirm or refute this possibility. However, we
found it remarkable that unlike MRSA, the BSSA-5 isolates accounted for
twice the proportion of the wound isolates associated with cefazolin
prophylaxis compared to the other prophylactic regimens. Furthermore,
BSSA-5 isolates are unique among S. aureus in their ability
to degrade cefazolin. Although cause and effect cannot be determined
from these data, the strong association between BSSA-5 wound infection
and cefazolin prophylaxis suggests that in vivo hydrolysis of cefazolin
may enable BSSA-5 to survive the perioperative period, thereby
contributing to the pathogenesis of these infections. We previously
have shown that type A
-lactamase-producing strains of S. aureus are associated with cefazolin-associated wound infections
(10). This earlier observation was due, in part, to the
common recovery of BSSA-5 isolates from wound infections in Nashville
and Salt Lake City without evidence of a common epidemiological link
among the infected patients.
There is an alternative hypothesis to explain the observed association between BSSA-5 and cefazolin prophylaxis that needs to be considered. The isolates evaluated in this study came from multiple hospitals which differed in the type of antibiotic prophylaxis used in surgery. It is possible that cefazolin prophylaxis was used more in hospitals where relatively resistant S. aureus strains were clustered. Although a randomized means of prophylactic regimen assignment would be required to completely rule out this possibility, the observation that the proportion of MRSA was virtually identical in S. aureus wound isolates from patients on cefazolin prophylaxis and in those from patients on other prophylactic regimens suggests that the likelihood of the wound being inoculated with resistant staphylococci was comparable for the two groups. Furthermore, surveillance cultures of specimens from the nares of cardiac surgery patients at the Nashville and Salt Lake City sites yielded 137 S. aureus isolates during this same period of time, only 12 (8.8%) of which were BSSA-5 (10a), suggesting that BSSA-5 was not especially common among patients undergoing surgery at these sites despite the strong association between BSSA-5 and wound infections failing cefazolin prophylaxis.
The observation that staphylococcal resistance may contribute to the
pathogenesis of some wound infections has important clinical implications. Resistant subpopulations of staphylococci may account for
a significant proportion of apparent prophylaxis failures; one-fourth
of the S. aureus isolates recovered from infected wounds associated with cefazolin prophylaxis in this study were BSSA-5. Because of elimination half-life and cost considerations, it would appear reasonable that surgeons continue to employ cefazolin as the
mainstay for perioperative prophylaxis in patients undergoing clean
surgical procedures. However, based on our observations, the isolation
of S. aureus from wound infections should be carefully monitored. A high or rising prevalence of BSSA-5 in association with
cefazolin prophylaxis should prompt a reevaluation of strategies of
perioperative prophylaxis with the consideration of using a more
-lactamase-stable agent.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported in part by PHS grant AI 32126 and a grant from Eli Lilly & Company, Indianapolis, Ind.
We thank Gary A. Hancock and J. Michael Miller of the Centers for Disease Control and Prevention for performing the phage typing assays. We thank Pat McGraw and Lyndell Weeks for technical assistance.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Infectious Diseases, A-3310 MCN, Vanderbilt University Medical Center, Garland and 21st Ave. South, Nashville, TN 37232-2605. Phone: (615) 327-4751, ext. 5512. Fax: (615) 321-6327. E-mail: kernodds{at}ctrvax.vanderbilt.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Barg, N.,
H. Chambers, and D. Kernodle.
1991.
Borderline susceptibility to antistaphylococcal penicillins is not conferred exclusively by the hyperproduction of -lactamase.
Antimicrob. Agents Chemother.
35:1975-1979 |
| 2. |
Bignardi, G. E.,
N. Woodford,
A. Chapman,
A. P. Johnson, and D. C. Speller.
1996.
Detection of the mecA gene and phenotypic detection of resistance in Staphylococcus aureus isolates with borderline or low-level methicillin resistance.
J. Antimicrob. Chemother.
37:53-63 |
| 3. | Chapin-Robertson, K., and S. E. Edberg. 1991. Measurement of antibiotics in human body fluids: techniques and significance, p. 295-366. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. Williams and Wilkins, Baltimore, Md. |
| 4. | Cuny, C., H. Claus, and W. Witte. 1996. Discrimination of S. aureus strains by PCR for r-RNA gene spacer size polymorphism and comparison to SmaI macrorestriction patterns. Zentralbl. Bakteriol. Hyg. Abt. 1 Orig. 283:466-476. |
| 5. |
Frimodt-Møller, N.,
S. H. Hartzen, and F. Espersen.
1985.
In vitro activity of methicillin against clinical isolates of Staphylococcus aureus.
J. Antimicrob. Chemother.
15:173-180 |
| 6. |
Gerberding, J. L.,
C. Miick,
H. H. Liu, and H. F. Chambers.
1991.
Comparison of conventional susceptibility tests with direct detection of penicillin-binding protein 2a in borderline oxacillin-resistant strains of Staphylococcus aureus.
Antimicrob. Agents Chemother.
35:2574-2579 |
| 7. | Kernodle, D. S., N. L. Barg, and A. B. Kaiser. 1988. Intrinsic methicillin resistance and phage complex 94/96 of Staphylococcus aureus. J. Infect. Dis. 157:396-397[Medline]. |
| 8. |
Kernodle, D. S.,
C. W. Stratton,
L. W. McMurray,
J. R. Chipley, and P. A. McGraw.
1989.
Differentiation of -lactamase variants of Staphylococcus aureus by substrate hydrolysis profiles.
J. Infect. Dis.
159:103-108[Medline].
|
| 9. | Kernodle, D. S., D. C. Classen, J. P. Burke, and A. B. Kaiser. 1990. Failure of cephalosporins to prevent Staphylococcus aureus surgical wound infections. JAMA 263:961-966[Abstract]. |
| 10. |
Kernodle, D. S.,
P. A. McGraw,
C. W. Stratton, and A. B. Kaiser.
1990.
Use of extracts versus whole-cell bacterial suspensions in the identification of Staphylococcus aureus -lactamase variants.
Antimicrob. Agents Chemother.
34:420-425 |
| 10a. | Kernodle, D. S., D. C. Classen, C. W. Stratton, and A. B. Kaiser. Unpublished data. |
| 11. | Kloos, W. E., and J. H. Jorgensen. 1985. Staphylococci, p. 143-153. In E. H. Lennette, A. Balows, W. J. Hausler, Jr., and H. J. Shadomy (ed.), Manual of clinical microbiology, 4th ed. American Society for Microbiology, Washington, D.C. |
| 12. | Lacey, R. W., and V. T. Rosdahl. 1974. An unusual "penicillinase plasmid" of Staphylococcus aureus: evidence for its transfer under natural conditions. J. Med. Microbiol. 7:1-9[Medline]. |
| 13. | Massidda, O., M. P. Montanari, M. Mingoia, and P. E. Varaldo. 1994. Cloning and expression of the penicillinase from a borderline methicillin-susceptible Staphylococcus aureus strain in Escherichia coli. FEMS Microbiol. Lett. 119:263-269[Medline]. |
| 14. |
McDougal, C. K., and C. Thornsberry.
1986.
The role of -lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins.
J. Clin. Microbiol.
23:832-839 |
| 15. | McMurray, L. W., D. S. Kernodle, and N. L. Barg. 1990. Characterization of a widespread strain of methicillin-susceptible Staphylococcus aureus associated with nosocomial infection. J. Infect. Dis. 162:759-762[Medline]. |
| 16. | National Committee for Clinical Laboratory Standards. 1990. Approved standard M7A2. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. National Committee for Clinical Laboratory Standards, Villanova, Pa. |
| 17. | Novick, R. P. 1963. Analysis by transduction of mutations affecting penicillinase formation in Staphylococcus aureus. J. Gen. Microbiol. 33:121-136[Medline]. |
| 18. | Panlilio, A. L., D. H. Culver, R. P. Gaynes, S. Banerjee, T. S. Henderson, J. S. Tolson, and W. J. Martone. 1992. Methicillin-resistant Staphylococcus aureus in U.S. hospitals. Infect. Control Hosp. Epidemiol. 13:582-586[Medline]. |
| 19. | Richmond, M. H. 1965. Wild type variants of exopenicillinase from Staphylococcus aureus. Biochem. J. 94:584-593. |
| 20. | Rosdahl, V. T. 1973. Naturally occurring constitutive beta-lactamase of novel serotype in Staphylococcus aureus. J. Gen. Microbiol. 77:229-231[Medline]. |
| 21. | Rosdahl, V. T., and K. Rosendal. 1983. Correlation of penicillinase production with phage type and susceptibility to antibiotics and heavy metals in Staphylococcus aureus. J. Med. Microbiol. 16:391-399[Abstract]. |
| 22. | Schaberg, D. R., D. H. Culver, and R. P. Gaynes. 1991. Major trends in the microbial etiology of nosocomial infection. Am. J. Med. 91(Suppl. 3B):72S-75S. |
| 23. | Siboni, A. H., K. T. Jensen, V. T. Rosdahl, and J. Gaub. 1995. Is methicillin better than cloxacillin in serious infections caused by strong penicillinase-producing staphylococci (phage-type 94/96)? Ugeskr. Laeg. 157:1862-1864[Medline]. |
| 24. |
Sierra-Madero, J. G.,
C. Knapp,
C. Karaffa, and J. A. Washington.
1988.
Role of -lactamase and different testing conditions in oxacillin-borderline-susceptible staphylococci.
Antimicrob. Agents Chemother.
32:1754-1757 |
| 25. | Smith, P. B. 1972. Bacteriophage typing of Staphylococcus aureus, p. 431-441. In J. O. Cohn (ed.), The staphylococci. John Wiley and Sons, New York, N.Y. |
| 26. |
Tomasz, A.,
H. B. Drugeon,
H. M. de Lencastre,
D. Jabes,
L. McDougall, and J. Bille.
1989.
New mechanism for methicillin resistance in Staphylococcus aureus: clinical isolates that lack the PBP 2a gene and contain normal penicillin-binding proteins with modified penicillin-binding capacity.
Antimicrob. Agents Chemother.
33:1869-1874 |
| 27. | Varaldo, P. E., M. P. Montanari, F. Biavasco, E. Manso, S. Ripa, and F. Santacroce. 1993. Survey of clinical isolates of Staphylococcus aureus for borderline susceptibility to antistaphylococcal penicillins. Eur. J. Clin. Microbiol. Infect. Dis. 12:677-682[Medline]. |
| 28. |
Zierdt, C. H.,
I. K. Hosein,
R. Shively, and J. D. MacLowry.
1992.
Phage pattern-specific oxacillin-resistant and borderline oxacillin-resistant Staphylococcus aureus in U.S. hospitals: epidemiological significance.
J. Clin. Microbiol.
30:252-254 |
| 29. |
Zygmunt, D. J.,
C. W. Stratton, and D. S. Kernodle.
1992.
Characterization of four -lactamases produced by Staphylococcus aureus.
Antimicrob. Agents Chemother.
36:440-445 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|